Trial results

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

NCT06058585 on ClinicalTrials.gov · last registry update 2026-10-05

An unusually large phase 3: 2,000 participants, more than double the 424 typical for the stage. Due to report 31 December 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Core Primary Outcome Measure. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 4 September 2024 — 2 years so far. semaglutide is already approved in the US for chronic kidney disease, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

RECRUITING

Phase

P3

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

The George Institute

Sponsor type

Other

Enrollment

2,000

Started

2024-09-04

Primary completion

2029-12-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Core Primary Outcome Measure

Conditions studied

Chronic Kidney Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.